Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA
Main finding · MACEResult — go to the resultHazard ratio 2.16 95% CI 1.57–2.99Authors' conclusion
Measurement of CAC may enhance value of care with weight loss dose semaglutide in those without diabetes or clinical CVD, improving allocation of a limited health care resource.
Study context
- Population
- MESA participants without DM or clinical cardiovascular disease (CVD) meeting BMI criteria for semaglutide, with coronary artery calcium (CAC) scoring on noncontrast cardiac CT49% had CAC
- Participants
- 3,129 participants
- Exposure
- CAC ≥300 vs CAC = 0
- Outcome
- Major adverse cardiovascular events (MACE)
Methodological detailsSELECT trial risk reductions applied to observed incidence rates
- SELECT trial risk reductions applied to observed incidence rates
Main finding
As reported in the abstract
Hazard ratio
2.16
95% CI 1.57–2.99
P < 0.001
By group
CAC = 0
653
5-year NNT (semaglutide)
CAC ≥300
79
5-year NNT (semaglutide)
CAC ≥300vs CAC = 0
HR 2.16 (95% CI 1.57–2.99); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | CAC = 0 | CAC ≥300 | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| HF | 2.80 (1.81–4.35) | P < 0.001 | |||
| 5-year NNT (semaglutide) | 1,094 | 144 | |||
| CKD | 1.59 (1.15–2.22) | P = 0.006 | |||
| 5-year NNT (semaglutide) | 1,044 | 144 | |||
| All-cause mortality | 1.35 (1.08–1.69) | P = 0.009 | |||
| 5-year NNT (semaglutide) | 408 | 98 | |||
| 0.20.5125Hazard ratio (log scale) |
Original publication
Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA. JACC Cardiovasc Imaging. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →